Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score.

ABSTRACT:

Objective

To characterize a novel "worst"-symptom visual analogue scale (WS-VAS) versus the traditional dyspnea visual analogue scale (DVAS) in an acute heart failure (AHF) trial.

Background

AHF trials assess symptom relief as a pivotal endpoint with the use of dyspnea scores. However, many AHF patients' worst presenting symptom (WS) may not be dyspnea. We hypothesized that a WS-VAS may reflect clinical improvement better than DVAS in AHF.

Methods and results

AHF patients (n = 232) enrolled in the Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF) Trial indicated their WS at enrollment and completed DVAS and WS-VAS at enrollment and 24, 48, and 72 hours. Dyspnea was the WS in 61%, body swelling in 29%, and fatigue in 10% of patients. Clinical c

SUBMITTER: AbouEzzeddine OF 

PROVIDER: S-EPMC4916018 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature